Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 3, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely updates the share capital and voting rights figures as of November 30, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors
- Issued Share Capital: As of November 30, 2018, GSK had 5,375,801,312 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,961,195,362.
- Regulatory Use: This voting rights figure serves as the denominator for shareholders calculating notification requirements under FCA rules.